Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Surfing the MASH Tsunami
43.1 2020 Year in Review: Advances in Fatty Liver Disease Drugs and Diagnostics
Vlad Ratziu discusses a "boiling hot" field of emerging NASH drugs and "particularly rich" data coming from no-invasive diagnostic testing.
Despite elafibranor failing, obeticholic acid not securing FDA approval and COVID-19 related limitations in the conduct of clinical trials, "this was a very good year actually for NASH clinical trials," with "some significant advances in terms of therapeutics for NASH" and . We had the results of several trials this year. We had the unfolding story of other molecules that are in development for NASH and all this makes for a very, very vibrant environment in terms of therapeutic research for NASH." Further, MRI-based methods "are becoming mainstream," starting to fulfill the promise of non-invasive testing.